Efficacy of Early Switching From Docetaxel to Cabazitaxel in Castration‐Resistant Prostate Cancer
Early switching to cabazitaxel after three cycles of docetaxel may reduce symptomatic adverse events, including peripheral neuropathy, while enabling longer chemotherapy exposure and improved PFS in patients with CRPC.
Authors
- Aya Niimi
- Shigenori Kakutani (ORCID: https://orcid.org/0000-0002-7772-6921)
- Taketo Kawai (ORCID: https://orcid.org/0000-0002-7279-2874)
- Daisuke Yamada (ORCID: https://orcid.org/0000-0002-2296-6653)
- Jun Kamei (ORCID: https://orcid.org/0000-0002-0069-7392)
- Kazuki Maki
- Tappei Takada (ORCID: https://orcid.org/0000-0002-3868-9320)
- Takehiro Tanaka
- Satoru Taguchi (ORCID: https://orcid.org/0000-0002-1291-4294)
- Jimpei Miyakawa (ORCID: https://orcid.org/0000-0003-1684-5772)
- Yuta Yamada (ORCID: https://orcid.org/0000-0002-9698-4301)
- Yoichi Fujii (ORCID: https://orcid.org/0000-0001-5436-2259)
- Haruki Kume
- Tohru Nakagawa (ORCID: https://orcid.org/0000-0003-4041-7241)
Institutions
- University of Tokyo Hospital (JP)
- The University of Tokyo (JP)
- International University of Health and Welfare (JP)
- Teikyo University (JP)
Publication Details
- Journal
- The Prostate
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1002/pros.70082
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Tokyo